Format

Send to

Choose Destination
Haematologica. 2015 Jun;100(6):e223-5. doi: 10.3324/haematol.2014.118034. Epub 2015 Mar 13.

High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia.

Author information

1
Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Sweden.
2
Department of Biosciences and Nutrition and Center for Innovative (CIMED), Karolinska Institutet, Sweden.
3
Science for Life Laboratory, Department of Biochemistry and Biophysics, Stockholm, Sweden.
4
Department of Biosciences and Nutrition and Center for Innovative (CIMED), Karolinska Institutet, Sweden Molecular Neurology Research Program, University of Helsinki and Folkhälsan Institute of Genetics, Helsinki, Finland.
5
Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Sweden Eva.Hellstrom-Lindberg@ki.se.

KEYWORDS:

acute myeloid leukemia; high-throughput mutational screening; myelodysplastic syndromes; secondary; therapy-related

PMID:
25769547
PMCID:
PMC4450634
DOI:
10.3324/haematol.2014.118034
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center